Fiona Blackhall

Summary

Affiliation: Christie Hospital
Country: UK

Publications

  1. ncbi request reprint Erlotinib in non-small cell lung cancer: a review
    Fiona H Blackhall
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Expert Opin Pharmacother 6:995-1002. 2005
  2. ncbi request reprint Small cell lung cancer and targeted therapies
    Fiona H Blackhall
    Christie Hospital NHS Trust, Manchester, UK
    Curr Opin Oncol 19:103-8. 2007
  3. pmc Evaluation and validation of a robust single cell RNA-amplification protocol through transcriptional profiling of enriched lung cancer initiating cells
    Dominic G Rothwell
    Nucleic Acid Biomarker Laboratory, Clinical and Experimental Pharmacology, CR UK Manchester Institute, University of Manchester, Manchester M20 4BX, UK
    BMC Genomics 15:1129. 2014
  4. pmc Integrated molecular portrait of non-small cell lung cancers
    Vladimir Lazar
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    BMC Med Genomics 6:53. 2013
  5. doi request reprint The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer
    Fiona Blackhall
    Department of Medical Oncology, Christie Hospital, Manchester, UK
    Lung Cancer 79:101-3. 2013
  6. pmc Clinical expert guidelines for the management of cough in lung cancer: report of a UK task group on cough
    Alex Molassiotis
    School of Nursing, University of Manchester, UK
    Cough 6:9. 2010
  7. doi request reprint Treatment of limited small cell lung cancer: an old or new challenge?
    Fiona Blackhall
    Department of Medical Oncology, the Christie NHS Foundation Trust, Manchester, UK
    Curr Opin Oncol 23:158-62. 2011
  8. doi request reprint A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer
    Fiona H Blackhall
    Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom
    J Thorac Oncol 5:1285-8. 2010
  9. doi request reprint Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial
    Rovel Colaco
    Department of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, UK
    Lung Cancer 76:72-7. 2012
  10. doi request reprint Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial
    Hamid Sheikh
    Dept of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, UK
    Lung Cancer 74:75-9. 2011

Collaborators

Detail Information

Publications32

  1. ncbi request reprint Erlotinib in non-small cell lung cancer: a review
    Fiona H Blackhall
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Expert Opin Pharmacother 6:995-1002. 2005
    ..This paper reviews the pharmacology, preclinical and clinical data to support the use of erlotinib in NSCLC...
  2. ncbi request reprint Small cell lung cancer and targeted therapies
    Fiona H Blackhall
    Christie Hospital NHS Trust, Manchester, UK
    Curr Opin Oncol 19:103-8. 2007
    ..Small cell lung cancer is a chemosensitive malignancy, yet long-term survival remains elusive for the majority of patients. Here, we report on progress in evaluating novel targeted therapies for the treatment of this disease...
  3. pmc Evaluation and validation of a robust single cell RNA-amplification protocol through transcriptional profiling of enriched lung cancer initiating cells
    Dominic G Rothwell
    Nucleic Acid Biomarker Laboratory, Clinical and Experimental Pharmacology, CR UK Manchester Institute, University of Manchester, Manchester M20 4BX, UK
    BMC Genomics 15:1129. 2014
    ..Here we demonstrate that the EpiStem RNA-Amp™ methodology reproducibly generates microgram amounts of cDNA suitable for RNA-Seq, RT-qPCR arrays and Microarray analysis...
  4. pmc Integrated molecular portrait of non-small cell lung cancers
    Vladimir Lazar
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    BMC Med Genomics 6:53. 2013
    ..The objectives of this study were to utilize integrated genomic data including copy-number alteration, mRNA, microRNA expression and candidate-gene full sequencing data to characterize the molecular distinctions between AC and SCC...
  5. doi request reprint The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer
    Fiona Blackhall
    Department of Medical Oncology, Christie Hospital, Manchester, UK
    Lung Cancer 79:101-3. 2013
    ....
  6. pmc Clinical expert guidelines for the management of cough in lung cancer: report of a UK task group on cough
    Alex Molassiotis
    School of Nursing, University of Manchester, UK
    Cough 6:9. 2010
    ..The aim of the present paper is to present a clinical guideline developed in the UK through scrutiny of the literature and expert opinion, in order to aid decision making in clinicians and highlight good practice...
  7. doi request reprint Treatment of limited small cell lung cancer: an old or new challenge?
    Fiona Blackhall
    Department of Medical Oncology, the Christie NHS Foundation Trust, Manchester, UK
    Curr Opin Oncol 23:158-62. 2011
    ..This review highlights how progress has been made in treating limited small cell lung cancer and outlines current challenges to overcome for improved cure rates...
  8. doi request reprint A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer
    Fiona H Blackhall
    Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom
    J Thorac Oncol 5:1285-8. 2010
    ..Vandetanib is a once-daily oral agent that selectively inhibits vascular endothelial growth factor receptor, epidermal growth factor receptor, and RET (REarranged during Transfection) signaling...
  9. doi request reprint Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial
    Rovel Colaco
    Department of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, UK
    Lung Cancer 76:72-7. 2012
    ..Routine ENI omission will be further evaluated prospectively in the ongoing phase III CONVERT trial (NCT00433563)...
  10. doi request reprint Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial
    Hamid Sheikh
    Dept of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, UK
    Lung Cancer 74:75-9. 2011
    ....
  11. doi request reprint Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group
    Raffaele Califano
    Department of Medical Oncology, the Christie NHS Foundation Trust, Manchester, United Kingdom
    Lung Cancer 73:338-44. 2011
    ..The role of chemotherapy for advanced NSCLC patients and ECOG PS2 remains controversial. We evaluated 4 doses of 3-weekly docetaxel to identify a less toxic, clinically effective dose...
  12. doi request reprint Antivascular agents for non-small-cell lung cancer: current status and future directions
    Eitan Amir
    Christie Hospital NHS Trust, Department of Medical Oncology, Manchester, UK
    Expert Opin Investig Drugs 18:1667-86. 2009
    ..Attention over recent years has focused, therefore, on targeted therapies, with notable success in the development of antivascular drugs...
  13. ncbi request reprint Sequential platinum-based chemotherapy-thoracic radiotherapy in early stage non-small cell lung cancer
    Nick Thatcher
    CRC Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 9BX, United Kingdom
    Clin Cancer Res 11:5051s-5056s. 2005
    ....
  14. doi request reprint Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment
    Neil A Bayman
    Department of Clinical Oncology, Christie Hospital, Manchester, UK
    Clin Lung Cancer 9:92-101. 2008
    ..The potential role of novel and targeted therapies and radiation dose escalation is also considered. Finally, recommendations are made for the treatment of unresectable stage III NSCLC...
  15. pmc Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer
    Emma J Dean
    Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK
    Neoplasia 13:339-47. 2011
    ..However, the preclinical data and the absence of a peak in circulating caspase-cleaved CK18 in trial patients suggest suboptimal timing of blood sampling, which will need refinement in future trials incorporating obatoclax...
  16. ncbi request reprint Targeting blood vessels for the treatment of non-small cell lung cancer
    Ethan Amir
    Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom
    Curr Cancer Drug Targets 8:392-403. 2008
    ....
  17. doi request reprint Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells
    Rachel Stovold
    Faculty of Life Sciences, Manchester Academic Health Sciences Centre, University of Manchester, AV Hill Building, Manchester, M13 9PT, UK
    Lung Cancer 76:263-8. 2012
    ..Here we review these studies, their implications for future research and for the incorporation of biomarkers reflecting neuroendocrine, epithelial and mesenchymal phenotypes in clinical studies...
  18. doi request reprint Gefitinib for the treatment of non-small-cell lung cancer
    Lynn Campbell
    Christie Hospital NHS Foundation Trust, Medical Oncology, Wilmslow Road, Manchester, UK
    Expert Opin Pharmacother 11:1343-57. 2010
    ..Recent trials of the small-molecule EGFR inhibitor gefitinib have now more clearly defined indications for usage, and clinical and molecular factors predictive of benefit...
  19. ncbi request reprint Perspectives on novel therapies for bronchial carcinoma
    Fiona Blackhall
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK
    Expert Opin Pharmacother 6:1157-67. 2005
    ..In this article the recent and ongoing Phase II and III trials of these therapies in lung cancer are summarised, and the prospects for their further clinical development are discussed...
  20. ncbi request reprint Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic
    Emma J Dean
    Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, United Kingdom
    Cancer Treat Rev 33:203-12. 2007
    ..This review reports the progress being made in characterising the IAP family, with a focus on the available data relevant to the treatment of lung cancer...
  21. ncbi request reprint X-linked inhibitor of apoptosis protein as a therapeutic target
    Emma J Dean
    Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Expert Opin Ther Targets 11:1459-71. 2007
    ..This review introduces XIAP from its molecular origins, discusses its modulation and potential as a novel drug target, and considers future therapeutic perspectives...
  22. doi request reprint The Manchester cough in lung cancer scale: the development and preliminary validation of a new assessment tool
    Alex Molassiotis
    School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, United Kingdom
    J Pain Symptom Manage 45:179-90. 2013
    ..Cough is a common distressing symptom in lung cancer patients. Its assessment is hampered by the lack of a validated scale to measure the complex cough experience in this population...
  23. pmc Circulating tumor cells as a window on metastasis biology in lung cancer
    Jian Mei Hou
    Clinical and Experimental Pharmacology Group, University of Manchester, Manchester, United Kingdom
    Am J Pathol 178:989-96. 2011
    ..Multiplex analysis and further detailed exploration of metastatic potential and EMT in CTCs/CTM is now warranted in a larger patient cohort...
  24. ncbi request reprint Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer : a realistic goal?
    Fiona H Blackhall
    Christie Hospital NHS Trust, Manchester, England, United Kingdom
    Treat Respir Med 4:71-84. 2005
    ....
  25. doi request reprint How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?
    Neil Bayman
    Department of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, UK
    Lung Cancer 83:117-25. 2014
    ....
  26. doi request reprint Clinical utility of circulating tumour cell detection in non-small-cell lung cancer
    Alberto Fusi
    Department of Medical Oncology, the Christie NHS Foundation Trust, Wilmslow Road, Withington, Manchester, M20 4BX, UK
    Curr Treat Options Oncol 14:610-22. 2013
    ..For the everyday clinician and clinical trialist, it will be important to maintain knowledge of the strengths and weaknesses of the technologies and evolving evidence base for CTCs as a routinely used diagnostic tool...
  27. doi request reprint Extrapulmonary small cell carcinoma: a clinicopathological study with identification of potential diagnostic mimics
    Anne Marie Quinn
    Department of Pathology, Manchester Royal Infirmary, Manchester, UK
    Histopathology 61:454-64. 2012
    ..To evaluate the clinicopathological features of small cell carcinoma arising outside the lung...
  28. ncbi request reprint Interstitial lung disease in lung cancer: separating disease progression from treatment effects
    Sarah Danson
    Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester M20 4BX, UK
    Drug Saf 28:103-13. 2005
    ..Treatment, at present, is supportive and includes discontinuation of gefitinib, oxygen supplementation, high-dose corticosteroids and antibacterials...
  29. pmc Hypoxic human cancer cells are sensitized to BH-3 mimetic–induced apoptosis via downregulation of the Bcl-2 protein Mcl-1
    Luke R E Harrison
    Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom
    J Clin Invest 121:1075-87. 2011
    ....
  30. ncbi request reprint Chemotherapy for advanced non-small cell lung cancer patients with performance status 2
    Fiona H Blackhall
    Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK
    Curr Opin Oncol 17:135-9. 2005
    ..In this article, we focus on the available literature for patients with a PS of 2, in whom a role for chemotherapy has yet to be defined...
  31. ncbi request reprint Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer
    Fiona H Blackhall
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX England, UK
    Hematol Oncol Clin North Am 18:1121-41, ix. 2004
    ..In this article, the evidence that supports a role for angiogenesis in the pathogenesis of lung cancer, trials of antiangiogenic agents in lung cancer performed to date, and the lessons learned from these studies are discussed...
  32. pmc Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy
    Jian Mei Hou
    Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research, Wilmslow Road, Manchester, M20 4BX, UK
    Am J Pathol 175:808-16. 2009
    ..Our results provide a rationale to include the use of serological biomarkers and CTCs in early clinical trials of new agents for small cell lung cancer...